Search results

Found 14909 matches for

ERGO is launching ALERRT, a multi-disciplinary consortium building a patient-centered clinical research network to respond to epidemics across sub-Saharan Africa. ALERRT aims to reduce the public health and socio-economic impact of disease outbreaks in sub-Saharan Africa by building a sustainable clinical and laboratory research preparedness and response network.

Mamadu Camara

Susanna Dunachie

Proochista Ariana

Buddha Basnyat

Celine Caillet

Trudie Lang

Thuong Thuong Nguyen

Thomas Peto

Richard Price

Jeanne Salje

Sompob Saralamba

James Watson

Sreymom Pol

Janjira Thaipadungpanit

Richard Hoglund

Raph Hamers

Nattwut Ekapirat

Sazid Ibna Zaman

Jahirul Karim

Vicki Marsh

Risks of serious adverse events following treatment for visceral leishmaniasis

30 March 2021

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

23 March 2021

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

19 March 2021

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

17 March 2021

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

16 March 2021

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

5 March 2021

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

Search results

Found 14909 matches for

Similar stories